Pfizer vaccine 95% effective in final analysis, company seeks final safety step
Pfizer and partner BioNTech said Wednesday the company will apply for FDA emergency authorization "within days," following the promising final analysis of the Phase 3 trial.
The drug company Pfizer said Monday that early analysis showed its candidate for Covid-19 is more than 90 percent effective in preventing infection. Aired on 11/9/2020. AstraZeneca says late-stage trials showed that its COVID-19 vaccine candidate with Oxford University was up to 90 per cent effective in preventing disease. AstraZeneca is the third major drug company to report late-stage results for its potential vaccine.
»» Progress is quickly being made in the race for a coronavirus vaccine. AstraZeneca says the vaccine it is developing at Oxford University in London is highly effective in older adults. This is the third vaccine to show promise in recent weeks, and it could be available alongside the vaccines being developed by Pfizer and Moderna. Charlie D'Agata discusses how the AstraZeneca vaccine differs from the other two. A vaccine developed at Oxford University has shown to have 90% effectiveness in preventing coronavirus.